Mirador is a next-generation precision medicine company focused on immunology and inflammation. The company’s Mirador360 TM precision development engine leverages the latest advances in human genetics and cutting-edge data science to rapidly advance new precision medicines for patients living with chronic immune-mediated inflammatory and fibrotic diseases. Launched in 2024, Mirador has raised over $400 million from leading life sciences investors and is based in San Diego, CA. 

Mirador Therapeutics

HSTS

Google Font API

CrUX Dataset

CrUX Top 5m

Akismet

Akismet Non Hosted

Linode

SMTP2GO

Market Research Manager

Juliana C.

Kristina Burow

Gregg Gilbert

Mark McKenna

Founder, Chairman & CEO

West Coast Therapeutics Companies

California Health Care Companies (Top 10K)

West Coast Health Care Companies (Top 10K)

Health Care Companies With Fewer Than 100 Employees (Top 10K)

Mirador Therapeutics envisions precision medicine for immune-mediated inflammatory and fibrotic diseases.

ARCH Venture Partners

Series A - Mirador Therapeutics

Debt Financing - Mirador Therapeutics

Venture Round - Mirador Therapeutics

San Diego

California

United States

North America

23andMe and Mirador Therapeutics Enter Into Strategic Research Collaboration to Advance Mirador’s Precision Medicines for Immunology & Inflammation

Mirador Therapeutics Appoints Gregg Gilbert at Chief Financial Officer

Health And Biotech Startups Now Get The Majority Of US Series A Funding

This biotech startup got the biggest venture capital deal in San Diego so far this year

Most-Active US Investors: General Catalyst Tops March’s List

North American Startup Investment Perked Up A Bit In Q1

The 10 Biggest Rounds Of March: Wonder, Biotech Headline Big Month

Mirador Therapeutics–OrbiMed: investment, 202403 Mirador emerges with total of >$400m in financing incl early investor OrbiMed

Mirador Therapeutics Raises Over 400M in Funding

The Week’s 10 Biggest Funding Rounds: Wonder Delivers Largest Round Of Week

A precision development engine that leverages advances in human genetics and data science to accelerate the development of new precision medicines for immune-mediated inflammatory and fibrotic diseases.

Therapies developed based on individual patient genetics and biology to treat immune-mediated inflammatory and fibrotic diseases.

Programs focused on antibody discovery and protein engineering for the development of biotherapeutic candidates.

Management of biologics development and manufacturing to deliver clinical trial supplies across multiple studies.

Acquisition, organization, and harmonization of clinical and omic datasets to support precision analytics.

Development of neural network models and large language models to drive new insights and therapeutic hypotheses.

India

Asia

Philippines

Nigeria

Africa

Mexico

Small business lending platform for banks and other lenders

SPARK

Provider of wealth information management services

Private Client Resources

Provider of secure document collection and file management solutions

FileInvite

Provider of school management software and integrated web services

RenWeb

Provider of digital lending and account opening solutions for financial institutions

MeridianLink

Mirador is a biotechnology company focused on developing precision therapies for immune-mediated diseases.

Chief Financial Officer

Member of the Board of Advisors

SVP of Finance

VP of Finance/Controller

CFO, Mirador Therapeutics, Inc.

Vika Brough

Chief People Officer

EVP & Chief Human Resources Officer

Chief Human Resources Officer

Vice President, Human Resources

Chief People Officer at Mirador Therapeutics, Inc.,              Independent public board member

Nori Ebersole

Chairman and Chief Executive Officer

Venture Partner

Chairman of the Board

President

Chairman and Chief Executive Officer of Mirador Therapeutics I Chairman of Apogee Therapeutics I EY Entrepreneur of the Year

Executive Director Protein Engineering

Head of Antibody Engineering

Life Science Consultant

Director, Immunotherapeutic Design, Cancer Immunology Discovery (CID)

Guest Professor

Assistant Professor

Postdoctoral Fellow

Graduate Student

Head of Protein Engineering/ Structural Immunologist

Dirk Zajonc

Board Member

Chief Business Officer

SVP, Corporate Business Development and Investor Relations

Strategic Advisor

SVP, Chief Strategy Officer

Corporate Strategy Executive I Biotech Entrepreneur I Board Member

Jordan Zwick

Associate Director, Precision Genetics

Associate Director, Translational Genetics (formerly Functional Genomics)

Principal Scientist, Functional Genomics

Principal Scientist, Human Genetics

Senior Scientist, Human Genetics

Scientist, Statistical Genetics

Postdoctoral Research Fellow, Cardiovascular Genetics

Computational & Translational Genetics Leader | Coach | Board Member | DEI Advocate

Khanh-Dung Nguyen

Chief Scientific Officer

Manager

Chief Scientific Officer and Head of R&D

Chief Technology Officer and Head of R&D

Associate Director - Drug Product Formulation and Manufacturing

Group Leader

Scientist - Late Stage Formulation

Senior Scientist - Protein Formulation and Fill-Finish

Scientist - Non-viral Gene Delivery

Ph.D. Student - Cell Biology

Biotech executive, R&D

Olivier Laurent

Chief Legal Officer

General Counsel

Senior Corporate Counsel

Associate

Business Analyst

Legal Executive

Tim Andrews

Chief Medical Officer

Member Board of Directors

Biotech Executive, Physician Scientist, Chief Medical Officer, Board Member

Allison Luo

Executive Director

Director, Cancer Immunology Discovery

Senior Research Investigator II, Immuno Oncology Discovery

Team Lead, Immuno-Oncology Biology and Immuno-Oncology Resistance Biology

Project Scientist/Instructor - Tumor Microenvironment

Postdoctoral fellow, Laboratory of 2019 Lasker Award winner Professor Max Cooper

Executive Director, Immunology, Mirador Therapeutics

Murali Gururajan

Chief Strategy Officer

President and Chief Medical Officer

Co-Founder and Chief Medical Officer

Co-Founder

Professor of Medicine and Vice Chair, Division of Gastroenterology and Hepatology

Biotech Executive, Board Member, Physician Scientist, Serial Entrepreneur, Professor, Key Opinion Leader, and Academic Leader

news impact assignment basic	general	May 3, 2024 5:46 AM	013809aa
public peers	general	May 3, 2024 5:46 AM	9f99e53d
news daily refresh	general	Sep 3, 2024 1:40 PM	614ab349
news processing daily refresh	general	Sep 3, 2024 2:34 PM	88d033ff
news impact assignment daily	general	Sep 3, 2024 9:53 AM	f6c36524
news processing basic	general	May 3, 2024 5:46 AM	ec6a1dcc
company summary	general	Aug 25, 2024 5:41 PM	e31fd6ac
signals	general
crunchbase trigger	general	Nov 25, 2024 9:06 AM	9b46d483
crunchbase profile	general	Nov 25, 2024 11:40 AM	ed3bae7f
li profile	general	May 3, 2024 5:46 AM	5968b2d2
translate crunchbase fundingrounds	general	Nov 25, 2024 2:09 PM	42693645
peers	general
news basic	general	May 3, 2024 5:46 AM	75876145
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:MIRADORTX

Mirador